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Abstract (abridged) 
 In this thesis, I applied aminoacylation ribozyme “flexizyme” to discover the 
novel interaction between a small non-coding RNA (ncRNA) and a small molecule, and 
to develop the orthogonal translation machinery consisting of the pair of ribosome and 
tRNAs bearing mutations at the peptidyl transferase center. Flexizymes have following 
unique characteristics; (i) substrate RNA is recognized by two consecutive base pairs 
between 3′-end of substrate RNA and 3′-end of flexizyme, (ii) these base pairs can be 
substituted with other base pairs and (iii) various activated amino acids can be used as 
substrates including both canonical and noncanonical amino acids. This flexible 
aminoacylation of RNAs by flexizymes were used not only as a method for labeling 
endogenous tRNAs but also as a tool to prepare various aminoacyl-tRNAs bearing 
mutations at 3′-end to engineer the translation machinery. 
 Chapter 1 is a general introduction of this thesis. Transfer RNA, translation and 
small non-coding RNA such as miRNA are firstly introduced, and the problems and 
questions in these research field are also described. Then aminoacylation ribozyme 
“flexizyme” having unique characteristics is introduced, which has a potential to 
overcome these problems.  
 In chapter 2, novel interaction between human small ncRNA and a small 
molecule is described. 
 In chapter 3, orthogonal translation machinery consisting of ribosome-tRNAs 
pair bearing compensatory mutations at the peptidyl transferase center is reported. The 
method to easily prepare various aminoacyl tRNA bearing mutations at 3′-end was 
developed by using compensatory mutated flexizymes. Next, translation activity of 
several mutant ribosome and tRNAs were investigated using FIT (Flexible In vitro 
Translation) system. Consequently, it was discovered that a certain mutant pair of 
ribosome and tRNAs had comparable translation activity and orthogonality to the wild-
type pair of ribosome and tRNAs. Finally two different peptides was expressed 
simultaneously in one pot from a single mRNA template using the mutant and wild-type 
ribosome–tRNA pair. 
 Chapter 4 is the conclusion of the entire thesis. Achievements of the studies and 
new insights obtained in this thesis are included. Finally, perspective of the potential 
application of aminoacylation by flexizymes for other studies is discussed. 
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Chapter 2 and some parts of chapter 1 and 4 are not shown due to the reasons 
involving submission of the paper. All references are included in this text. 
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Chapter 1 
General introduction (abriged) 
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1.1. Transfer RNA 
 Genetic information is transcribed from DNA into mRNA (messenger RNA) and 
mRNA is translated into protein, and this process is called as central dogma (Figure 1). 
By human genome project, it was reported that only the 2% region of human genomic 
DNA is transcribed and translated to about 20,000-25,000 proteins1, but transcriptome 
study revealed that about 70% region of DNA is transcribed to RNA. In addition, 
widespread transcription of non-coding RNAs with important functions throughout the 
genome have been recently discovered2. 
Transfer RNA (tRNA) is one of the most abundant and popular non-coding 
RNAs, which works as an adaptor molecule linking the language of nucleotide to the 
language of amino acid in the translation step. Canonical tRNA forms cloverleaf 
secondary structure and L-shaped tertiary structure as shown in Figure 2. Aminoacyl-
tRNA sythetase (ARS) charge corresponding amino acid onto the 3′-end of specific tRNA 
to produce aminoacyl-tRNA (aa-tRNA) and aa-tRNA is recruited into ribosome by 
translation factors (Figure 1). Three consecutive nucleotides called as anticodon of tRNA 
forms base pairs with the sequential triplet codons of mRNA in the ribosome, and 
corresponding amino acid is incorporated into nascent peptide chain (Figure 1 and 2). The 
correspondence between codons and amino acids are defined as genetic code (Figure 3). 
This genetic code is well conserved in the most of all organisms (some exceptions have 
been found3) and accurate translation of mRNA to protein is essential for living organisms. 
CCA sequence at the 3′-end are universally conserved in all three domains, 
prokaryote, eukaryote and archaea. During the translation reaction, CCA-3′ end interacts 
with ribosome and translation factors, and it is important for efficient translation. In the 
aminoacylation step, ARSs strictly recognize the body sequences of substrate tRNAs to 
charge specific amino acids onto specific tRNAs. In addition, because most ARSs also 
interact with the universally conserved CCA-3′ end of tRNAs4,5, it is difficult to prepare 
the various aa-tRNAs bearing mutations in the CCA-3′ end by ARSs6-8. To prepare such 
aa-tRNAs, so-called “chemical acylation” method where chemically synthesized 
aminoacyl-nucleotide was ligated to tRNA lacking the 3′-end by T4 RNA ligase9,10 may 
be usable. However, in this method, it is laborious work that various aminoacyl-nuleotides 
are prepared by chemical synthesis. If the easy method to prepare various aa-tRNA 
bearing mutation in the CCA-3′ end, it is usable for analyzing the role of CCA-3′ end 
during the translation and engineering the translation machinery.    
9 
 
 
Figure 1 | Schematic illustration of central dogma. “AA” in the red circle 
indicate amino acid. An image of protein was prepared from crystal structure 
of GFP (green fluorescent protein) (PDB ID: 1GFL)11. 
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Figure 2 | Structure of tRNA. (a) Clover leaf structure of tRNA. Conserved 
bases are described, circles represent non-conserved bases, and numbers 
indicate the nucleotide position. Positions 34 to 36 (dark blue) form 
corresponds to the anticodon and position 74 to 76 (red) are universally 
conserved as CCA. The sequences composing the intron and the extra bases 
presenting in the variable loop (position noted 47 to 47k) are shown as black 
line. AAS (magenta), the amino acid-accepting stem; DSL (green), the 
dihydrouridine stem and loop; ASL (cyan), the anticodon stem and loop; VL 
(black); the variable loop, TSL (orange); the thymidine stem and loop, Y; 
pyrimidine, R; purine, H; not G, D; not C. The n bases at position 17, 17a, 
20a and 20b are optional bases not present in all tRNAs. Position -1 bases are 
found in all cytoplasmic mature tRNAHisGUG from the three biological 
domains. This figure was adapted from the previous paper12. (b) L-shaped 
tertiary structure of tRNA. Each color indicates the same region described in 
Figure 2a. This image was prepared from crystal structure of Saccharomyces 
cerevisiae tRNAPhe (PDB ID: 1EHZ)13.  
  
a b 
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Figure 3 | Standard genetic code. All 64 codons were assigned to 
corresponding amino acids or termination signal (termed as “Stop” in this 
figure). 
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1.2. Other non-coding RNAs than tRNAs 
 As I mentioned above, tRNA is one of the most abundant and popular non-coding 
RNA (ncRNA). In addition to tRNA, ribosomal RNAs (rRNAs) are also known as popular 
ncRNA, which constitute a ribosome. There are three kinds of rRNAs (5S, 16S and 23S 
rRNAs) in prokaryote, and four kinds of rRNAs (5S, 5.8S, 18S and 28S rRNA) in 
eukaryote. Peptidyl transfer reaction, which makes a peptide bond, is catalyzed by 23S 
rRNA or 28S rRNA. These tRNA and rRNA are much abundant and account for about 
95% of all RNAs in mammalian cells14. 
 The various other ncRNAs than tRNA and rRNA have been identified mainly in 
mammalian15. These ncRNAs are roughly classified into two groups; long ncRNA (longer 
than 200 nt) and small ncRNA (smaller than 200 nt)16,17. Unlike small ncRNA such as 
microRNA, function of long ncRNA has been less studied. However, recent studies 
revealed the broad functional repertoire including roles in high-order chromosomal 
dynamics, telomere biology and subcellular structural organization18,19. 
 The class of small ncRNA includes various RNAs such as snRNAs (small 
nuclear RNAs), snoRNAs (small nucleolar RNAs) and miRNAs (micro RNAs)20. snRNA 
makes complex with protein to form snRNP (ribonucleoprotein) and consists of 
spliceosome involving the reaction of mRNA splicing. snoRNA generally ranges from 60 
to 300 nucleotides in length and guide the site-specific modification of nucleotide in target 
RNA21. In the past few years, about 22 nt short ncRNA (miRNA) has been widely studied. 
miRNA is loaded into Ago protein to form a RISC (RNA induced silencing complex)22. 
A RISC binds to target mRNA via base pairs between miRNA and 3′-UTR (untranslated 
region) of mRNA to inhibit the translation and suppress the expression of the target gene. 
To date more than 1,800 miRNAs in human are registered in databases (miRbase23, 
http://www.mirbase.org/) and are estimated to regulate the expression of more than 60% 
of genes to control a wide range of biological processes including proliferation, 
differentiation, apoptosis and development15. 
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1.3. Aminoacylation ribozyme “flexizyme” 
 In order to achieve these requirements described in former sections; I focused 
attention on the unique characteristics of flexizymes which is in vitro selected 
aminoacylation ribozyme24,25. First, I briefly summarize how to develop the artificial 
ribozyme. 
A ribozyme which is an RNA having catalytic activity which was first discovered 
in nature in 1980s26,27. These discoveries indicated RNA can store information like DNA 
and catalyze chemical reaction like proteins to strongly support the “RNA world 
hypothesis” that the origin of life may have relied on RNA28. However, the chemical 
reactions catalyzed by natural ribozymes are limited to the cleavage or ligation of the 
RNA phosphodiester backbone except for peptidyl transfer by ribosome29. To expand the 
variety of chemical reactions catalyzed by RNA, in vitro selection of ribozyme have been 
developed. SELEX (Systematic Evolution of Ligands by EXponential enrichment, or in 
vitro selection) is a method based on molecular evolution engineering to identify the 
active molecules having specific activities from pools of various compounds30,31. It was 
first reported from two groups in 1990 and they discovered RNA aptamers binding to 
specific target molecules from random RNA library. In addition to discovery of aptamers, 
the molecules having catalytic activities such as ribozyme have also been identified32. A 
general scheme of SELEX of active RNAs was shown in Figure 4. DNA library 
containing T7 promoter sequence, 5′-constant sequence, random sequences and 3′-
constant sequence is prepared by PCR. These constant sequences are used for following 
reverse transcription and PCR reaction. The DNA templates are transcribed to RNAs by 
T7 RNA polymerase in vitro. From the RNA library, portion of RNAs are selected based 
on their ability to carry out a specific function (e.g. binding affinity and catalytic activity). 
Selected RNAs are converted to cDNAs by reverse transcription. These cDNAs are 
amplified by PCR and the same procedure is repeated. After the several times repeats of 
this process, the resulting RNA fraction will be enriched with functional molecules with 
the desired activity. By SELEX, many artificial ribozymes have been discovered33 (e.g. 
RNA polymerization33-35, alcohol oxidation36, Diels-Alder reaction37 and 
aminoacylation38-42). Among them, aminoacylation ribozymes were important because 
these are candidates as key molecules which link the ancient RNA world with modern 
protein world.  
In nature, ARS catalyze aminoacylation reaction. Aminoacylation by ARS 
involves two steps; (i) activation of carboxyl group amino acids by adenylation using ATP 
to yield aminoacyl-adenosine monophosphate (aminoacyl-AMP), and (ii) condensation 
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of aminoacyl-AMP and tRNA to yield aminoacyl-tRNA (aa-tRNA). Although no 
ribozyme catalyzing these both reactions have been discovered in nature, some artificial 
ribozymes catalyzing (i) or (ii) step were identified by in vitro selection. The KK13 
ribozyme catalyze the activation of amino acid by using the 5′-triphosphate of RNA 
instead of ATP43. The #29 ribozyme family catalyzes cis-acyl transfer reaction using 
aminoacyl-AMP to produce both aminoacyl- and peptidyl-tRNAs38,44,45, and the C3 
ribozyme family consisting of only three essential nucleotides catalyze both cis- and 
trans-acyl transfer reaction using aminoacyl-AMP42,46. Flexizyme is also trans-acyl-
transfer ribozyme using activated amino acids, which was developed by SELEX method 
and was engineered to aminoacylate various activated amino acids. There are three types 
of flexizymes, dFx (dinitrobenzyl flexizyme)41, eFx (enhanced flexizyme)41 and aFx 
(amino flexizyme)47 (Figure 5). dFx charges wide variety of amino acid whose carboxyl 
group is activated with 3,5-dinitrobenzyl ester (DBE), eFx charges aromatic amino acids 
activated with cyanomethyl ester (CME) or nonaromatic amino acids with 4-chlorobenzyl 
thioester (CBT), and aFx charges substrates activated with benzyl thioester group bearing 
a protonated primary amine (ABT).These flexizymes can charge wide variety of amino 
acids including noncanonical amino acids (ncAAs) such as N-methyl-amino acids48-50, N-
alkyl-glycines51, cyclic N-alkyl amino acids52, N-acyl-amino acids53, exotic peptides54, α-
hydroxy acids49,55, and D-amino acids56 onto tRNAs.  
In addition to the characteristic to charge diverse kinds of amino acids, 
flexizymes have the flexibility to aminoacylate the substrate tRNA bearing any body 
sequence because flexizymes recognize the CCA-3′ end by two consecutive base pairs 
with GGU-3′ of flexizymes40,57,58 (Figure 5 and 6). The crystal structure of flexizyme 
fused with substrate minihelix RNA docked onto the tRNAs indicated the no interaction 
between flexizyme and body sequence of substrate tRNA57 (Figure 6). This is because, 
fleixizyme can aminoacylate other RNAs different from tRNAs even if those have single 
strand CCA-3′ end. In addition, in the experiment using prototype of flexizymes “pre-24”, 
these two consecutive base pairs are important for aminoacylation and this base pairs can 
be substituted with certain base pairs40,58.  
In summary, flexizymes have following unique characteristics; (i) substrate RNA 
is recognized by two consecutive base pairs between 3′-end of substrate RNA and 3′-end 
of flexizyme, (ii) these base pairs can be substituted with other base pairs and (iii) various 
activated amino acids can be used as substrates including both canonical and 
noncanonical amino acids. These features are different from natural protein ARSs and 
other aminoacylation ribozymes. From these characteristics of flexizymes, I considered 
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that flexizymes enable to achieve the requirements described early in this section.  
 
 
Figure 4 | General scheme of SELEX (in vitro selection) of functional 
RNAs. Black sequences are constant regions including the promoter sequence 
for T7 RNA polymerase and the 5′/3′-constant sequences necessary for 
reverse transcription and PCR amplification. Colored (blue, orange and red) 
sequences indicate the random region. This figure is adapted from the 
previous review25. 
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Figure 5 | Schematic illustration of aminoacylation by three derivatives 
of flexizymes and acyl-donor substrates with cognate leaving group. This 
figure is adapted from previous review25. Lines denote the Watson-Crick base 
pairs and bullets denote wobble base pairs. R represents amino acid side 
chains including noncanonical ones. X represent a-functional groups, such as 
amino, N-alkylamino, and hydroxy groups. LG; leaving group, dFx; 
dinitrobenzyl flexizyme, eFx; enhanced flexizyme, aFx; amino flexizyme, 
DBE; dinitrobenzyl ester, CME; cyanomethyl ester, CBT; p-
chlorobenzylthioester, ABT; amino-derivatized benzyl thioester. 
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Figure 6 | Structures of protein and RNA aminoacyl-tRNA synthetases. 
(a) Crystal structure of Escherichia coli glutamiyl-tRNA synthetase (GlnRS; 
orange) and tRNAGln complex (PDB ID: 1GTS)59. (b) Crystal structure of 
flexizyme (wheat color) docked onto E. coli tRNAGln by superimposing the 
minihelix on the ASL of the tRNA (PDB ID: 3CUL)57. 
 
 
 
a b 
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1.4. Removed for the reasons involving submission of the paper (a brief 
introduction of chapter 2)  
 
1.5. Development of orthogonal translation machinery (a brief 
introduction of chapter 3) 
 The CCA-3′ sequence of tRNA is conserved among all organisms and is 
important for aminoacylation and translation. In bacteria, the CCA-3′ end makes Watson-
Crick base pairs with bases of 23S rRNA in the peptidyl transferase center (PTC) in the 
classical state62 and translocation63 during translation. These base pairs are important for 
translation activity, and the compensatory mutations in these base pairs are tolerated 
during peptidyl transfer reaction64 and translocation63. However, it is yet empirically 
unknown whether such mutations accommodates translation in its entirety. 
 In chapter 3, I will report development of orthogonal translation machinery65. 
First, I developed method to easily aminoacylate various amino acids onto tRNAs bearing 
mutation (or mutations) in CCA-3′ end using compensatory mutated flexizymes. Then 
the translation activity of the PTC-mutated ribosomes and tRNAs were measured. 
Consequently, I developed the mutant ribosome and tRNA pair which had comparable 
translation activity and orthogonality to the wild-type ribosome and tRNA pair. Finally 
two different peptides was expressed simultaneously in one pot from a single mRNA 
template using the mutant and wild-type ribosome–tRNA pair. 
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Figure 7 | Overview of the thesis. 
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Chapter 2 
Removed for the reasons involving submission of the paper  
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Chapter 3 
Orthogonal ribosome-tRNAs pair by engineering of peptidyl 
transferase center 
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3.1. Introduction 
Assignment of 20 canonical amino acids to codons, is achieved by specific 
acylation of tRNA with cognate amino acid catalyzed by aminoacyl-tRNA synthetase 
(ARS). Since each tRNA has an anticodon that pairs with the codon, the codons on mRNA 
can be decoded by the cognate aminoacyl-tRNAs (aa-tRNAs) according to the genetic 
code; and thus ribosome is able to catalyze the formation of peptide bond along the mRNA 
template, to yield a polypeptide with the encoded sequence. While 20 canonical amino 
acids are used in the natural translation system, it has been demonstrated that more than 
hundreds of different noncanonical amino acids (ncAAs) can be incorporated into nascent 
polypeptide chain by engineering of the genetic code113. Assignment of ncAAs in the 
genetic code has been achieved by two methodologies: genetic code expansion114,115 and 
genetic code reprogramming116. The former method generally assigns a ncAA (or 
multiple ncAAs) to a nonsense codon(s) such as stop codons and an artificially 
programmed quadruplet codon(s). Genetic code expansion has been applied for both in 
vivo and in vitro expression of proteins with ncAAs.  
When the genetic code expansion is performed in vivo, availability of ncAA-
tRNA generally relies on an exogenously introduced ARS specifically paired with an 
orthogonal tRNA. The orthogonal tRNA should not be aminoacylated by endogenous 
ARSs. At the same time, the exogenous ARS should be engineered to specifically charge 
the ncAA onto the orthogonal tRNA, but not onto endogenous tRNAs. Several orthogonal 
ARS–tRNA pairs have been successfully developed113, and thus far demonstrated 
expression of proteins containing ncAAs. However, the choices of usable ncAAs are yet 
limited to a few subgroups, because the majority examples of the engineered ARSs are 
based on Methanococcus jannaschii TyrRS115, Methanosarcina barkeri PylRS117,118, or 
Methanosarcina mazei PylRS119,120; therefore, the usable ncAAs for these mutant 
enzymes are limited to Phe or Lys analogs. 
In addition to orthogonal ARS–tRNA pair, orthogonal ribosome–mRNA pair has 
been developed121. In this system engineered ribosome containing orthogonal 16S rRNA 
which does not recognizes endogenous mRNA but recognizes engineered mRNA bearing 
mutated Shine-Dalgarno (SD) sequence, was used121. Decoding center of this orthogonal 
16S rRNAs have been further evolved for efficient amber codon decoding122 and 
quadruplet codon123. These orthogonal ribosome–mRNA pairs enabled to express specific 
protein containing ncAAs in vivo124. However, the numbers of usable ncAAs and codons 
were still limited. 
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On the other hand, in the genetic code reprograming, multiple sense codons can 
be simultaneously reassigned with various ncAAs. Genetic code reprogramming has been 
dominantly utilized in in vitro reconstituted translation system125 to produce short 
polypeptides containing diverse exotic ncAAs such as D-amino acids56 and N-methyl-
amino acids48-50. Although in the genetic code reprogramming method, multiple ncAAs 
can be incorporated, some canonical amino acids cannot be used simultaneously. It is 
because the canonical amino acids originally assigned in natural genetic code need to be 
removed to suppress the incorporation of canonical amino acids instead of ncAAs126. To 
overcome this problem in genetic code reprogramming, I conceived the new concept of 
orthogonal translation system, which is orthogonal ribosome–tRNA pair. This engineered 
translation system means that wild-type ribosome only use canonical aa-tRNAs and the 
engineered ribosome only use ncAA-tRNAs as substrates. In this system, it is not 
necessary to deplete canonical amino acids and to change the original genetic code in 
order to incorporate ncAAs. 
To develop the orthogonal ribosome–tRNA pair, the interaction between 
ribosome and tRNA needs to be engineered. During the elongation cycle of bacterial 
translation, where amino acids were sequentially added to the growing peptide chain, 
CCA-end of tRNA interacts with 23S rRNA of 30S subunit. The elongation cycle is 
divided to three steps127,128 (Figure 18). First step is accommodation of aa-tRNA into the 
A-site of ribosome. aa-tRNA is delivered to the A-site by EF-Tu•GTP in the A/T state 
where the anticodon forms base pairs with codon in the A-site of 30S and the acceptor 
end is bound to EF-Tu (the first letter represents the binding site on the 30S and the second 
letter the site on the 50S). Then GTP is hydrolyzed to GDP to release EF-Tu•GDP and the 
accommodation of the acceptor end of the aa-tRNA into the A-site of the 50S (A/A state, 
the classical state). Second is peptide bond formation between aa-tRNA in A/A state and 
peptidyl-tRNA in P/P state, which is catalyzed in the peptidyl transferase center (PTC). 
After the peptide bond formation, peptidyl-tRNA in A/A state is translocated to P/P state 
and deacylated tRNA in P/P state is translocated to E/E state facilitated by EF-G with 
associated GTP hydrolysis, which is the third step. 
In the PTC of classical state of E. coli ribosome complex, critical Watson-Crick 
base pairs occur between the universally conserved 3′ end of tRNAs (C74 and C75) and 
23S rRNA G2251 and G2252 at the P site as well as G2553 at the A site, which were 
revealed by biochemical experiments and crystal structural analyses62,129-136 (Figure 17 
and 19a). Using an analogue of aa-tRNA fragment (C75 mutant puromycin derivatives of 
the form NPm) as an A-site substrate (Figure 19b and c), peptidyl transfer activity of 
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wild-type and G2553N mutant ribosome 50S subunits was measured by Kim and Green64. 
They reported that the wild-type ribosome preferred the wild-type substrate (CPm) by 
about 2- to 5-fold relative to the other substrates (APm, GPm and UPm) (Figure 19b). 
Furthermore, G2553C ribosome preferred the compensatory mutated substrate (GPm) by 
at least 20-fold relative to the other three substrates (Figure 19c). These results indicated 
that G2253C ribosome-GPm pair has weak orthogonality to wild-type ribosome-CPm 
pair in peptidyl transfer reaction.  
The first step of translocation is movement of acceptor end of peptidyl-tRNA in 
A/A state into A/P state and acceptor end of deacylated tRNA in P/P state into P/E state, 
which is called as hybrid state127 (Figure 18 and 20). This first step is promoted by EF-
G•GTP but it can occur in the absence of GTP137. Then EF-G promotes translocation of 
peptidyl-tRNA from the A/P state to the P/P state and deacylated tRNA from the P/E state 
to the E/E state to be released from the ribosome. To my knowledge, there is no direct 
evidence of the interaction between 23S rRNA and CCA-end of tRNAs during the hybrid 
state. However, Dorner et. al. indicated the potential pairs between C74/C75 of peptidyl-
tRNA in the A/P state and G2252/G2251 of 23S rRNA in the P-site63 (Figure 20). In this 
report, they measured EF-G translocation rate with the pairs of wild-type and mutant 
ribosomes and tRNAs (Table 7 and 8). When C74G tRNA is in A-site of wild-type 
ribosome, translocation rate reduced (Table 7). When potential pairing between tRNA in 
the A/P state and 23S rRNA in the P-site was restored (the pair of C74G tRNA and 
G2252C ribosome), translocation rate was restored (Table 7). Similar result was observed 
about the interaction between C75 of tRNA in the A/P state and G2251 of 23S rRNA 
(Table 7). These results indicates that the pair of G2251C or G2252C ribosome and C75G 
or C74G tRNA have weak orthogonality to the pair of wild-type ribosome and tRNA in 
translocation. 
On the other hand, disruption of the interaction in the A/A state (the pairs of 
wild-type tRNA and G2253C/U/A ribosomes) increased the rate of translocation (Table 
8) and restoring the base pair in the A/A state (the pair of C75G tRNA and G2253C 
ribosome) diminished the translocation rate. These results indicate that ribosome and 
tRNAs favored the stable state forming base pairs.  
These studies described above showed that engineering the base pairs between 
G2251/G2252/G2553 of ribosome and C74/C75 of tRNAs in PTC had potential to 
develop the orthogonal ribosome–tRNA pairs. However, it was unknown whether a 
mutation (or mutations) of 23S rRNA and CCA-3′ end of tRNAs in the PTC affect the 
whole translation reaction to produce polypeptides using aa-tRNAs as substrates in an 
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mRNA-dependent manner, including other steps. 
In this chapter 3, I measured the translation activity of the PTC-mutated 
ribosome–tRNA pairs using an E. coli custom-made in vitro translation system that was 
integrated with the flexizyme technology, referred to as the FIT (Flexible In vitro 
Translation) system126. In natural, tRNAs are aminoacylated by protein aminoacyl-tRNA 
synthetases (ARSs) and ARSs specifically recognize the sequence of cognate tRNAs. 
Because most ARSs also interact with the universally conserved CCA-3′ end of tRNAs4,5, 
ARSs are not suitable for preparation of aminoacyl-tRNA (aa-tRNA) bearing mutation in 
the CCA-3′ end6-8. In order to overcome this problem, flexizymes (eFx and dFx) bearing 
compensatory mutated 3′ ends were used because flexizymes recognize CCA-3′ end of 
substrate RNA via base pairs as described in chapter 1. Finally, the pair of mutant 
ribosome and tRNAs which acted orthogonally and used only the cognate genetic code 
consisting of ncAAs65. 
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Figure 17 | Crystal structure of classical state of ribosome-tRNAs-mRNA 
complex. The interaction between 23S rRNA and CCA-end of tRNAs at the 
peptidyl transferase center (PTC) is shown in black rectangle. Black dashed 
lines indicate hydrogen bonds. This structure was reported in previous paper62 
(PDB ID: 2WDK/2WDL). 
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Figure 18 | Schematic illustration of elongation cycle of bacterial 
translation. The ribosomes are described as black rectangles and divided into 
30S and 50S subunits and partitioned into the A-, P- and E-sites. The biding 
states of the tRNAs as previously defined127 are indicated at the bottom of 
each sites. “Pep” means peptide and “AA” means amino acid. Bold lines 
indicate tRNAs.   
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Figure 19 | Peptidyl transfer reaction using G2553N mutant ribosome 
and C75 mutant puromycin derivatives64. The ribosomes are described as 
wheat ellipse and divided into 50S and 30S subunits. (a) Schematic 
illustration of natural peptidyl transfer between peptidyl-tRNA at P-site and 
aa-tRNA at A-site. (b) Schematic illustration of peptidyl transfer between N-
acetyl-phenylalanyl-tRNA (AcPhe-tRNA) at P-site and C75 puromycin 
derivatives shown as CPm at A-site using reconstituted wild-type 50S subunit. 
(c) Schematic illustration of peptidyl transfer between N-acetyl-phenylalanyl-
tRNA (AcPhe-tRNA) at P-site and C75G puromycin derivatives shown as 
GPm at A-site using reconstituted G2553C mutant 50S subunit.  
a b c 
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Figure 20 | Schematic illustration of classical and hybrid state of tRNA-
ribosome complex and translocation induced by EF-G–GTP. The 
ribosomes are described as black rectangles and divided into 30S and 50S 
subunits and partitioned into the A-, P- and E-sites. The biding states of the 
tRNAs as previously defined127 are indicated at the bottom of each sites. “Pep” 
in red circle means peptidyl-tRNA. Bold lines indicate tRNAs and bold Gs 
indicate G2251, G2252 and G2553 of 23S rRNA interacting with CCA-end 
of tRNAs. This figure was adapted from previous report63,138. 
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Table 7 | EF-G translocation of WT, G2252C and G2251C mutant ribosomes. This 
table was adapted from previous report63. 
  Translocation rate (s-1)   Translocation rate (s-1) 
P-site 
tRNA 
A-site 
tRNA WT G2252C 
P-site 
tRNA 
A-site 
tRNA WT G2251C 
WT WT 3.8 1.5 WT WT 3.8 2.1 
WT C74G 1.5 5.0 WT C75G 1.4 9.3 
 
  
Table 8 | EF-G translocation with WT and G2553 mutant ribosomes. ND indicates 
“not determined”. This table was adapted from previous report63. 
  Translocation rate (s-1) 
P-site 
tRNA 
A-site 
tRNA WT G2553C G2553U G2553A 
WT WT 3.8 10.7 12.2 12.4 
WT C75G 1.4 1.1 ND ND 
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3.2. Results and discussions 
 The study in this chapter 3 was published as a paper in the scientific journal and 
the figures in this chapter are reproduced or adapted from the published paper65. 
 
3.2.1. Aminoacylation of CCA-mutated tRNAs 
 To confirm that CCA-3′ end mutated tRNAs (denoted as tRNAs-NNA) can be 
aminoacylated by compensatory mutated flexizymes, I arbitrarily chose lysine and 
tyrosine as amino acids substrates (Figure 21), and tRNAAsnE2CUU and tRNA
AsnE2
GUA 
(Figure 22) bearing corresponding anticodons. Three mutant tRNAs derived from 
tRNAAsnE2CUU and tRNA
AsnE2
GUA bearing single or double C to G mutation (or mutations) 
(C74G, C75G or C74G/C75G) and the compensatory single or double G to C mutated 
flexizymes derived from dFx and eFx (Figure 5) were prepared by in vitro transcription. 
The aminoacylation efficiency were measured by acid-PAGE, which indicates the 
cognate mutant dFxs and eFxs can aminoacylate the tRNAs-NNA in the presence of Lys-
DBE and Tyr-CME (Figure 23). On the other hand, wild-type flexizymes could not 
aminoacylate non-cognate tRNA mutants (Figure 23). In the case of C75U tRNA mutant, 
aminoacylation efficiency of mutant flexizymes bearing GAU-3′ end, which form two 
Watson-Crick base pairs with tRNAs, was lower than that of wild-type bearing GGU-3′ 
end, which form one Watson-Crick base pair and one G•U wobble base pair (Figure 24). 
This result indicates that G•U wobble base pair is more suitable for aminoacylation by 
flexizymes than A-U Watson-Crick base pairs. Mutant flexizymes could also charge 
several other amino acids (Figure 21) onto the corresponding mutant tRNAs for further 
experiments (Figure 25). 
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Figure 21 | Amino acid substrates used in the chapter 3. The abbreviations 
of Fph, Aly, and Anv represent N-(5-FAM)-L-phenylalanine, L-acetyllysine, 
and L-azidonorvaline, respectively. Carboxyl groups were activated using 
cyanomethyl ester (CME) or 3,5-dinitrobenzyl ester (DBE). 
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Figure 22 | Secondary structures of transcribed (t.s.) tRNAs compared 
with native tRNAs of E. coli. The figure presents the secondary structures 
of tRNAfMetCAU (a), tRNA
AsnE2
NNN (b), tRNA
GluE2
NNN (c), tRNA
Lys
CUU (d), 
tRNAAspGUC (e), and tRNA
Tyr
GUA (f). s
4U; 4-thiouridine, D; dihydrouridine, 
Cm; 2′-O-methylcytidine, m7G; 7-methylguanosine, ψ; pseudouridine, Q; 
queuosine, ct6A: cyclic N6-threonylcarbamoyladenosine, mnm5s2U; 5-
methylaminomethyl-2-thiouridine, m2A; 2-methyladenosine, acp3U; 3-(3-
amino-3-carboxypropyl)uridine, T; ribothymidine, gluQ; glutamyl-queuosine, 
ms2i6A; 2-methylthio-N6-isopentenyladenosine. The sequences are based on 
the Modomics database139 (http://modomics.genesilico.pl/). 
 
  
a b 
c d 
e f 
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Figure 23 | A model study of aminoacylation of tRNAs-NNA derived from 
tRNAAsnE2. tRNAs were acylated by dFx in the presence of Lys-DBE (a), and 
eFx in the presence of Tyr-CME (b). Acid-PAGE separated the bands of aa-
tRNA (upper) and uncharged tRNA (lower). The data were generated from a 
sample of the end product of aminoacylation reaction. Note that the mobility 
of flexizymes was different depending on the 3′-terminal mutations. 
  
a
b 
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Figure 24 | Aminoacylation of tRNA-CUA derived from tRNAAsnE2. 
tRNAs were acylated by dFx in the presence of Lys-DBE (a), and eFx in the 
presence of Tyr-CME (b). Acid-PAGE separated the bands of aa-tRNA 
(upper) and uncharged tRNA (lower). The data were generated from a sample 
of the end product of aminoacylation reaction. 
  
a b 
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Figure 25 | Efficiency of flexizymes-catalyzed aminoacylation with 
canonical (Tyr, Lys, and Asp) and non-canonical (Fph, Aly, and Anv) 
amino acids. The tRNAs-CCA, -GCA, -CGA, -GGA and -CUA were 
acylated by the compensatory flexizymes, dFx/eFx-GGU, -GCU, -CGU, -
CCU and -AGU. The data represent the average of three independent 
reactions. The error bars represent the standard deviation. The data were 
generated from a sample of the end product of aminoacylation reaction. 
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3.2.2. Preparation of tagged ribosomes 
 Mutant ribosomes bearing a mutation (or mutations) at PTC were prepared using 
an MS2-tag affinity purification method140. Professor Rachel Green in Johns Hopkins 
University kindly gifted me a plasmid p278 MS2 (AmpR) encoding 23S rRNA inserted 
with MS2-tag sequence in helix 98 of 23S rRNA (Figure 26a), pcI857 (KanR) encoding a 
temperature-sensitive mutant of the lambda repressor protein cI and a plasmid pMAL-
c2g (AmpR) encoding His6-tagged MS2 coat protein fused with maltose binding protein 
(His6-MS2-MBP).  
The plasmids p278 MS2 bearing mutations at PTC were constructed by site-
directed mutagenesis. First, the plasmid pMAL-c2g was used to transform E. coli and 
His6-MS2-MBP was expressed to be purified by FPLC using Ni-NTA affinity column. 
Next, the plasmids pcI857 and p278 MS2 were used to transform E. coli. Because the 
mutant ribosomes may be toxic to E. coli, this transformed E. coli was pre-cultured at 
30°C where mutant ribosomes were not expressed and the temperature was increased to 
42°C to express the mutant ribosomes. His6-MS2-MBP was immobilized onto the MBP 
column by FPLC and the expressed tagged-ribosomes (wild-type, G2251C, G2252C, 
G2553C, G2251C/G2553C, G2251C/G2252C/G2553C and G2251A/G2553A) were 
purified by MS2 affinity purification using FPLC (Figure 26b). Contamination of wild-
type untagged-ribosome into the purified tagged-ribosomes were quantified by primer 
extension method140. This result showed the negligible contamination rate less than 3% 
(Figure 27). 
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Figure 26 | Schematic illustration of the insertion sites for the MS2 tag 
and purification of tagged ribosome. (a) Helix 98 in 23S rRNA which is the 
insertion sites for the MS2 tag was indicated as green circle. The image of 
structure was produced from the previous report 62 (PDB ID: 2WDK/2WDL). 
(b) Representative results of FPLC purification of MS2-tagged ribosome. 
  
a b 
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Figure 27 | Primer extension analysis of rRNAs extracted from MS2-
tagged ribosomes purified by FPLC. (a) A primer that is complementary to 
the bases of 2254–2273 in 23S rRNA was used for the detection of mutations 
of 2251 and 2252. (b) A primer that is complementary to the bases of 2556–
2575 in 23S rRNA was used for the detection of mutation of 2553. MS2-taggd 
ribosomes bearing mutations produced different ddGTP or ddTTP stops from 
those produced by WT ribosome. The abundance of tagged ribosomes relative 
to untagged wild-type in each population was shown below the gel. The 
calculated values of abundance were derived from a single experimental data 
set. 
  
a b 
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3.2.3. Translation activity of wild-type/mutant ribosome-tRNA pairs 
 An assay system to detect peptides translated by tagged-ribosomes and aa-
tRNAs-NNA was established. Because E. coli ARSs do not uniformly charge amino acids 
onto tRNAs-NNA6-8, a conventional methods using radioisotope-labeling amino acids is 
unsuitable. Instead, fluorescently-labeled amino acid (N-(5-FAM)-L-phenylalanine, Fph, 
Figure 21) was aminoacylated onto initiator tRNAfMetCAU and incorporated at N-terminus 
of peptide by FIT system126 to reassign the initiation codon from fMet to Fph. Lysine and 
tyrosine were charged onto tRNAAsnE2CUU-CCA and tRNA
AsnE2
GUA-CCA by cognate dFx 
and eFx, respectively. As a model template, a DNA template encoding the heptapeptide-
1 (Fph-Lys-Tyr-Lys-Lys-Tyr-Lys) was prepared and the expression of heptapeptide-1 in 
the FIT system, whose components were described in the section of materials and 
methods, was confirmed. Tricine-SDS-PAGE analysis of the translated product enabled 
to visualize a fluorescent band (Figure 28a) and quantify an expressed peptide by 
comparison with a band generated by a known concentration of Fph (Figure 28b), and the 
peak corresponding to heptatpeptide-1 was confirmed by MALDI-TOF-MS (Figure 28c). 
The production of heptapeptide-1 plateaued at 30 min, with a final concentration of 
approximately 1.0 µM. We also examined expression of heptapeptide-1 using Lys-
tRNAGluE2CUU-CCA and Tyr-tRNA
GluE2
GUA-CCA under the same condition, and the 
amount of expressed peptide increased to 3.5 µM (Figure 29a and b). The increase of 
expression rate could be attributed to the higher binding affinity of aa-tRNAsGluE2-CCA 
compared to aa-tRNAAsnE2-CCA (Figure 30). Therefore, we decided to use tRNAGluE2 for 
further translation experiments. 
 Next, I investigated whether tRNAs-NNA can be used by the wild-type ribosome 
for mRNA-dependent translation. Four mutant aa-tRNAs bearing GCA-3′, CGA-3′ and 
GGA-3′ were prepared by cognate dFxs and eFxs (Figure 25) and tested these expressions. 
Surprisingly tRNA-GCA could be used by wild-type ribosome to express heptapeptide-1 
even only one base pair forms at P-site and the final concentration of the peptide was 2.7 
µM (Figure 29). On the other hand, tRNAs-CGA and -GGA were inactive with wild-type 
ribosome (Figure 29). These results indicate that tRNAs-CGA and tRNAs-GGA but not 
tRNAs-GCA are orthogonal to the wild-type tRNAs-CCA (Figure 31). 
 Then, I measured the translation activity of mutant ribosomes and tRNAs. As 
predicted from the results with the pair of wild-type ribosome and non-cognate tRNAs-
GCA, the G2252C ribosome was also active with both cognate tRNAs-GCA and non-
cognate tRNAs-CCA, but not with tRNAs-CGA and tRNAs-GGA (Figure 29a). The 
expression rate of cognate pair of G2252C ribosome and tRNAs-GCA was almost the 
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same as that of wild-type pair, and that of non-cognate pair of G2252C ribosome and 
tRNAs-CCA was also the same as that of non-cognate pair of wild-type ribosome and 
tRNAs-GCA (Figure 29b). These both cognate and non-cognate pairs yielded 
heptapeptide-1 as major products (Figure 29c). These results indicated that mispair 
between G2252 and G74 or C2252 and C74 could be tolerated during the translation 
reaction. 
The double mutant ribosome G2251C/G2553C ribosome was sufficiently active 
with only cognate tRNAs-CGA to yield heptapeptide-1 (Figure 29). Time-course analysis 
indicated that expression plateaued at a final concentration of 1.7 µM. This suggests that 
the cognate pair of G2251C/G2553C ribosome and tRNAs-CGA functions orthogonally 
to the wild-type pair (Figure 31). However, this mutant pair has a slower translation rate 
than the wild-type pair, resulting in a lower yield of peptide due to the hydrolysis of the 
aa-tRNAs. Faint bands observed when using tRNAs-CCA and tRNAs-GCA could be 
ascribed to a peptide originating from the background translation by little amount (< 3%) 
of wild-type ribosome contamination to the respective mutant ribosome (Figure 27). 
When tRNAs-GGA was used, a very faint band was detected because mispair between 
G2252 and G74 was tolerated as described above. However, these bands were too faint 
to reliably quantify the intensity for the time-course experiment below and determine the 
product identity by MALDI-TOF analysis. 
 The triple mutant ribosome (G2251C/G2252C/G2553C) was active with only 
cognate tRNAs-GGA to yield heptapeptide-1 like the double mutant ribosome (Figure 
29). However, the translation rate dramatically decreased and the final concentration of 
heptapeptide-1 was 0.4 µM, which was reflected as a tiny peak of heptapaptide-1 in 
MALDI-TOF-MS spectrum (Figure 29c).  
I also tested the translational activity of other ribosome mutants 
(G2251A/G2553A, G2251C and G2553C) and tRNA mutant (tRNA-CUA) (Figure 32). 
Like G2251C/G2553 ribosome and G2251C/G2252C/G2553C ribosome, 
G2251A/G2553A ribosome was active with only cognate tRNA-CUA, but the band was 
too faint to reliably quantify the intensity for the time-course experiment and determine 
the product identity by MALDI-TOF analysis. A very faint band observed when using 
tRNAs-CCA could be due to the contamination of wild-type ribosome (Figure 27). These 
results indicate that A-U pair between 23S rRNA and tRNA is not appropriate for 
translation. In addition, wild-type ribosome was inactive with tRNAs-CUA, which 
suggests that G•U wobble pair between ribosome and tRNA at the PTC is not tolerated. 
In the case of G2251C and G2553C ribosomes, translation activity was not restored when 
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using tRNA-CCA or tRNA-CGA. This result and the fact that the pair of 
G2251C/G2553C ribosome and tRNA-CGA had comparable translation activity to wild-
type pair, combination of two base pairs, G2553-C75 at the A-site and G2251-C75 at the 
P-site, is essential for translation.  
These decrease of translation rate of cognate pair of mutant ribosome and tRNAs 
indicates that, despite the fact that PT activity and translocation activity of mutant 
ribosomes bearing mutations at PTC was restored by the compensatory mutations into 
CCA end of tRNAs63,64, these compensatory mutations did not fully restore the whole 
translation activity. This further suggests that these bases have crucial roles in not only 
the PT reaction and translocation but also other steps of translation, potentially involving 
interactions with other rRNAs or protein factors. It was confirmed that the binding affinity 
of aa-tRNAs-NNA to form ternary complexes (EF-TU•GTP•aa-tRNA) were almost the 
same as that of wild-type, which was coincident with the previous report130,141. In the 
accommodation step, C75 of tRNA pack between EF-Tu residue 219 and the flipped base 
of A55 of 16S rRNA, which is 99.5% conserved in all species of known sequence142. It 
is possible that these interaction is critical for efficient translation reaction. Nonetheless, 
further studies are necessary to elucidate why compensatory mutations at CCA-end could 
not fully restore the translation activity of mutant ribosomes.  
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Figure 28 | Translation activity of pairs of wild-type ribosome–tRNA 
using tRNAsAsnE2 as elongator tRNAs. (a) Tricine-SDS-PAGE analysis of 
heptapeptide-1 (FphLysTyrLysLysTyrLys) synthesized using the wild-type 
pairs of ribosome–tRNAs. tRNAfMetCAU bearing the CCA-3′ end were used as 
initiator tRNAs, and tRNAsAsnE2NNN (NNN denotes CUU and GUA 
designating Lys and Tyr, respectively) bearing the CCA-3′ end were used as 
elongator tRNAs. This image showed the result of the end of the translation 
reaction. Two bands were observed for Fph (indicated by Fph1 and Fph2), 
presumably due to the presence of Fph, Fph-CME and Fph-tRNAfMetCAU. The 
bands above and below of Fph1 showed truncated peptides generated by 
peptidyl-tRNA drop-off143 (b) Time-course analysis of heptapeptide-1 
production. The data represent the average of three independent reactions and 
error bars represent the standard deviation of the individual measurements. 
(c) MALDI-TOF MS analysis of heptapeptide-1. C and O denote calculated 
and observed mass values, respectively. † indicates a potassium adduct of 
heptapeptide-1. Other minor peaks were also present in the non-templated 
translation product likely originating from the translation system. The data 
were generated from a sample of the end product of translation reaction. 
a b 
c 
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Figure 29 | Translational activity of pairs of ribosome and tRNA mutants. 
(a) Tricine-SDS-PAGE analysis of heptapeptide-1 (Fph-Lys-Tyr-Lys-Lys-
Tyr-Lys) synthesized using the designated pairs of ribosome–tRNA mutants. 
tRNAsfMetCAU bearing the respective NNA-3′ end were used as initiator 
tRNAs, and tRNAsGluE2NNN (NNN denotes CUU and GUA designating Lys 
and Tyr, respectively) bearing the respective NNA-3′ end were used as 
elongator tRNAs. This image showed the result of the end of the translation 
reaction. (b) Time-course analysis of heptapeptide-1 production by active 
pairs of ribosomes and tRNAs. I investigated four cognate pairs of the wild-
type ribosome–tRNAs-CCA (cyan solid line), G2252C-ribosome–tRNAs-
GCA (yellow solid), G2251C/G2553C-ribosome–tRNAs-CGA (red solid), 
and G2251C/G2252C/G2553C-ribosome–tRNAs-GGA (purple solid), and 
two non-cognate pairs of the wild-type ribosome–tRNAs-GCA (black 
dashed) and G2252C-ribosome–tRNAs-CCA (brown dashed). The data 
represent the average of three independent reactions. The error bars represent 
the standard deviation. (c) MALDI-TOF MS analysis of heptapeptide-1 
synthesized using cognate and non-cognate ribosome–tRNA pairs. Lane 
numbers are those of the tricine-SDS-PAGE gel described in Figure 29. C and 
a b 
c 
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O denote calculated and observed mass values, respectively. † indicates a 
potassium adduct of heptapeptide-1. ‡ indicates the molecular mass value 
consistent with FphLysTyrLysLysTyr, which was presumably produced by 
peptidyl-tRNA drop-off143. The identity of major peak in lane 16 is unknown; 
however, since this peaks as well as other minor peaks were also present in 
the sample of G2251C/G225C/G2553C-ribosome alone, it could be 
originated from a contaminant of the G2251C/G225C/G2553C-ribosome 
preparation. The data were generated from a sample of the end product of 
translation reaction. 
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Figure 30 | Gel-shift assay for ternary complex of elongation factor Tu 
(EF-Tu), guanosine triphosphate (GTP) and aa-tRNAs-CCA, GCA, CGA 
and GGA. Tyrosine was charged onto tRNAAsnE2GUA and tRNA
GluE2
GUA, and 
lysine was charged onto tRNAAsnE2CUU and tRNA
GluE2
CUU. Band intensities of 
the ternary complexes were normalized relative to EF-Tu, GTP and aa-
tRNAs-CCA complexes. The values of the relative intensity of the ternary 
complex (y-axis) were derived from a single experimental set. 
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Figure 31 | Illustration of compatibility and orthogonality of the 
ribosome–tRNAs mutant pairs. Line thickness indicates the compatibility 
of translational activity between each ribosome–tRNA pair. 
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Figure 32 | Translational activity of pairs of ribosome–tRNA mutants 
bearing CCA, GCA, CGA, GGA and CUA-3′ ends. tRNAsfMet were used 
as initiator tRNAs and tRNAsGluE2 as elongator tRNAs. (a) The entire 
image of the tricine-SDS-PAGE analysis of a heptapeptide-1 
(FphLysTyrLysLysTyrLys) synthesized using pairs of ribosome–tRNA 
mutants. This image showed the result of the end of the translation reaction. 
The bands above and below of Fph1 showed truncated peptides generated by 
peptidyl-tRNA drop-off143, which were also observed for the wild-type 
control of lane 1. The faint bands in lanes 3, 8, 9 and 13 could be ascribed to 
a peptide originating from the background translation by little amount (< 3%) 
of wild-type ribosome contamination to the respective mutant ribosome 
(Figure 27). (b) Time-course analysis of heptapeptide-1 production by active 
pairs of ribosomes and tRNAs. Lane numbers are those of the tricine-SDS-
PAGE gel described in Figure 32a, in which the solid line in cyan indicates 
the reaction of a cognate pairs of the wild-type ribosome–tRNAs-CCA (the 
identical result shown in Figure 29b) while the dashed line in yellow shows 
that of a non-cognate pair G2253C-ribosome–tRNAs-CCA. The data 
represent the mean value of each sample (n = 3) and error bars show the 
standard deviations obtained from independent measurements. (c) MALDI-
TOF MS analysis of heptapeptide-1 synthesized using a non-cognate pair 
G2253C-ribosome–tRNAs-CCA. Lane numbers are those of the Tricine-
SDS-PAGE gel described in Figure 32a. C and O denote calculated and 
observed mass values, respectively. ‡ indicates the molecular mass value 
consistent with FphLysTyrLysLysTyr, which could be one of the bands 
corresponding to the truncated peptides appeared in the tricine-SDS-PAGE. 
The data shown in Figure 32a and c were generated from a sample of the end 
product of translation reaction.  
a b 
c 
79 
 
3.2.4. Simultaneous expression of two different peptides from single 
mRNA template 
 Because the pair of G2251C/G2553C ribosome and tRNAs-CGA had 
comparable translation activity and orthogonality to the wild-type ribosome and tRNA-
CCA pair, I examined whether two distinct peptides could be expressed from a single 
mRNA template under artificially programmed genetic code in one pot. Four amino acids 
were assigned to the respective genetic codes as follows; For the wild-type ribosome–
tRNAs pair, a genetic code (referred to as WT-code) assigned Fph (AUG, initiation), 
lysine (AAG), tyrosine (UAC) and aspartic acid (GAC), and for the G2251C/G2553C 
ribosome–tRNAs-CGA pair, an orthogonal genetic code (referred to as OR-code) 
assigned Fph (AUG, initiation), lysine (AAG), L-azidonorvaline (Anv; UAC) and L-
acetyllysine (Aly; GAC) (Figure 33). The tRNAs-CCA and tRNAs-CGA were 
aminoacylated with respective amino acids using wild-type or compensatory mutated 
flexizymes. The DNA template encoding heptapeptide-2 according to the WT-code and 
heptapeptide-3 according to the OR-code was added to the FIT system, which comprised 
the combination of the wild-type ribosomes. G2251C/G2553C ribosomes and/or the 
above aa-tRNAs (Figure 34a). 
 In the presence of wild-type ribosome and wild-type aa-tRNAs-CCA, 
heptapeptide-2 was expressed according to WT-code (Figure 34 b-d). When aa-tRNAs-
CGA was added into wild-type pair of ribosome and aa-tRNAs-CCA, only heptapeptide-
2 was observed in tiricine-SDS-PAGE and MALDI-TOF-MS spectrum without any 
hybrid products (for example, Fph-Lys-Anv-Asp-Lys-Tyr-Aly, [M+H]+ = 1313.51) 
generated from potential cross-reading (or readings) of codons in non-cognate genetic 
code (Figure 34 b and c). This indicates that aa-tRNAs-CGA was not used as translation 
substrates by wild-type ribosome. Similarly, the mutant pair of G2251C/G2553C 
ribosome and aa-tRNAs-CGA or this pair with the wild-type aa-tRNAs-CCA yielded only 
heptapeptide-2 (Figure 34 b-d). The decrease of peptide expression was observed in the 
presence of one ribosome with both cognate and non-cognate aa-tRNAs (Figure 34 c and 
d). This decreased expression of peptide could not be restored by increasing EF-Tu 
concentrations from 10 µM to 20 µM, which rules out EF-Tu sequestration by the non-
cognate aa-tRNAs as an explanation for this effect (Figure 35). From this result and the 
fact that the affinity of aa-tRNAs-CCA to EF-Tu was almost the same as that of aa-
tRNAs-CGA (Figure 30), it is possible that ternary complex including non-cognate aa-
tRNAs compete with that including cognate aa-tRNAs in accommodation step. 
Nonetheless, further studies are necessary to restore this decrease of expression rate. 
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 In the presence of both wild-type and mutant pair of ribosome and aa-tRNAs, 
the desired both heptapeptide-2 and -3 were expressed from a single DNA template in 
one pot according to the WT- and OR-codes (Figure 34). In the absence of DNA template, 
no peptide was observed (Figure 34c), which is consistent with the observation that 
translation proceeded in an mRNA-dependent manner. Moreover, the same experiment 
using different DNA template and aa-tRNAs produced two different heptapeptides from 
one DNA template (Figure 36 and 37).  
 In these experiments, two distinct peptides can be expressed from one DNA 
template without any hybrid products. These results indicate that these coexisting 
translational machineries acted orthogonally and used only the cognate genetic codes. 
 
 
Figure 33 | Two genetic codes programmed for simultaneous expression 
of two distinct peptides from a single mRNA sequence. (a) WT-code. This 
code comprises the wild-type ribosome–tRNAs-CCA pair. (b) OR-code. This 
code comprises the G2251C/G2553C-ribosome–tRNAs-CGA pair. 
  
a b 
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Figure 34 | Simultaneous expression of two distinct peptides from a single 
mRNA sequence under two artificially programmed genetic codes. (a) 
Schematic illustration of simultaneous expression. The wild-type ribosome–
tRNAs-CCA and G2251C/G2553C-ribosome–tRNA-CGA pairs generated 
heptapeptide-2 and heptapeptide-3, respectively, according to the WT- and 
OR-codes. (b) MALDI-TOF MS analysis of translational products. 
Calculated (C) and observed mass (O) values are shown in the right panel of 
the spectra. † and ‡ denote a potassium adduct of heptapeptide-2 and 
heptapeptide-3, respectively. ¶ denotes heptapeptide-3 whose azide group 
was reduced to a primary amino group presumably by thiols present in the 
FIT system144. Since other minor unidentified peaks were present in the non-
templated translation product, they are likely present in the translation system. 
The data shown in Figure 34b and c were generated from a sample of the end 
product of translation reaction. (c) Tricine-SDS-PAGE analysis of the 
respective heptapeptides. (d) Time-course analysis of simultaneous 
a b 
c 
d 
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expression of heptapeptides. Heptapeptide-2 expression is seen in lane 1 
(black dashed line), lane 2 (purple) and lane 5 (cyan, simultaneous 
expression); heptapeptide-3 expression is seen in lane 3 (brown dashed line) 
lane 4 (yellow) and lane 5 (red, simultaneous expression). Lane numbers are 
those described in Figure 34c. The data represent the average of three 
independent reactions and error bars represent the standard deviation. 
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Figure 35 | Time-course analysis of heptapeptide production with an 
elevated concentration of EF-Tu. The concentration of EF-Tu was increased 
to 20 µM from 10 µM which was the condition in the experiments in Figure 
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34. (a) Production of heptapeptide-2 when wildype ribosome coexisted with 
cognate aa-tRNAs-CCA and noncognate aa-tRNA-CGA with 20 µM EF-
Tu/Ts were shown as green dashed line. (b) Production of heptapeptide-3 
when orthogonal ribosome coexisted with its noncognate and cognate aa-
tRNAs with 20 µM EF-Tu/Ts were shown as pink dashed line. (c) Production 
of heptapeptide-2 and -3 when both ribosomes with all aa-tRNAs coexisted 
with 20 µM EF-Tu/Ts were shown as blue and orange dashed lines. The other 
lines represent the same result as those shown in Figure 34d. Lane numbers 
are those described in Figure 34c. The data represent the average of three 
independent reactions, and the error bars represent the standard deviation of 
the individual measurements. 
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Figure 36 | Simultaneous expression of two heptapeptides-4 and -5 from 
a single mRNA template according to the two artificially programmed 
genetic codes. (a) Peptide translation from a single mRNA sequence in a 
single reaction mixture. The pair of wild-type ribosome–tRNAs-CCA and 
G2251C/G2553C-ribosome–tRNA-CGA generated Fph-Lys-Asp-Lys-Lys-
Asp-Lys (heptapeptide-4) and Fph-Lys-Aly-Lys-Lys-Aly-Lys (heptapeptide-
5), respectively, according to their respective genetic codes. (b) Tricine-SDS-
PAGE analysis of the respective heptapeptides, 4 and 5. Other faint based are 
truncated peptides generated by peptidyl-tRNA drop-off143. (c) MALDI-TOF 
MS of the peptides isolated by gel filtration. Calculated (C) and observed 
mass (O) values are shown in the right panel of the spectra. † indicates the 
potassium adduct of heptapeptide-4, ‡ indicates the potassium adduct of 
heptapeptide-5, *species also present in the “no template” translation product 
and were likely derived from the translation mixture. The data shown in 
Figure 36b and c were generated from a sample of the end product of 
translation reaction. 
a b 
c 
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Figure 37 | Simultaneous expression of two heptapeptides-1 and -6 from 
a single mRNA template according to the two artificially programmed 
genetic codes. (a) Peptide translation from a single mRNA sequence in a 
single reaction mixture. The pair of wild-type ribosome–tRNAs-CCA and 
G2251C/G2553C-ribosome–tRNA-CGA generated Fph-Lys-Asp-Lys-Lys-
Asp-Lys (heptapeptide-1) and Fph-Lys-Anv-Lys-Lys-Anv-Lys 
(heptapeptide-6), respectively, according to their respective genetic codes. (b) 
Tricine-SDS-PAGE analysis. Heptapeptides-1 and -6 could were observed at 
the same position. Other faint based are truncated peptides generated by 
peptidyl-tRNA drop-off143. (c) MALDI-TOF MS of the peptides isolated by 
gel filtration. Calculated (C) and observed mass (O) values are shown in the 
right panel of the spectra. † indicates the potassium adduct of heptapeptide-1, 
‡ indicates the potassium adduct of heptapeptide-2, ¶ indicates heptapeptide-
6 whose azide group was reduced to a primary amino group presumably by 
thiols present in the FIT system144, *species also present in the “no template” 
translation product and were likely derived from the translation mixture. The 
data shown in Figure 37b and c were generated from a sample of the end 
product of translation reaction. 
a b 
c 
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3.3. Conclusion 
 In this chapter, I developed the method to prepare aa-tRNAs-NNA using 
compensatory mutated flexizymes. Then, I measured the translation activity of PTC-
mutated ribosome–tRNA pair and developed the orthogonal ribosome–tRNAs pair. 
 First, CCA-3′ end mutated tRNAs were aminoacylated with various amino acids 
by compensatory mutated flexizymes. In addition to C74N/C75N mutants, A76N mutant 
tRNA also can be aminoacylated by prototype of flexizymes “pre-24”40,58, which 
indicates that also compensatory mutated flexizymes (eFx, dFx and aFx) can 
aminoacylate A76N mutant tRNAs. From other groups, an efficient method to prepare 
homogeneous aa-tRNAs using flexizyme was recently reported145. These results indicate 
that wild-type and compensatory mutated flexizymes have great potential to charge 
various amino acids onto any RNA substrates bearing NNN-3′ end. 
 Next, translation activity of several mutant ribosome–tRNAs pairs were 
measured. To my knowledge, this is the first report about the whole translation activity of 
CCA-3′ end mutated tRNAs and compensatory mutated ribosome although peptidyl 
transfer64 and translocation63 of those were already reported. Compensatory mutation of 
23S rRNA in the PTC restored the whole translation activity, which is consistent with the 
results of peptidyl transfer64 and translocation63. However, compensatory mutations did 
not fully restore the activity of some mutant ribosome–tRNAs pairs. To fully restore the 
translation activity, more engineering of translation machinery including other positions 
of rRNAs and translation factors will be required. 
 Finally, orthogonal mutant ribosome–tRNAs functioning independently to wild-
type ribosome–tRNAs according to artificially designed genetic code. Combination of 
wild-type and orthogonal ribosome–tRNAs pair can produce two different peptides from 
one mRNA. Unfortunately, the efficiency of translation was decreased when both cognate 
and non-cognate tRNA were present with ribosomes. To increase the translation efficiency, 
the more detailed interaction of CCA-3′ end with ribosomes and translation factors should 
be investigated and more engineering of translation machinery will be required. 
 The study in this chapter 3 established a novel method for genetic code 
reprogramming, and also demonstrated the importance of interactions between the rRNA 
and the tRNAs in translation. These results open an entrance to a new opportunity of in 
vitro synthetic biology involving the engineering of the genetic codes and translation 
machineries. 
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3.4. Materials and methods 
 The experiments in this chapter were conducted mainly following the methods 
in the previous report65. 
 
Chemical synthesis of L-tyrosine cyanomethyl ester (Tyr-CME), L-aspartic acid 3,5-
dinitrobenzyl ester (Asp-DBE), L-lysine 3,5-dinitrobenzyl ester (Lys-DBE), L-
acetyllysine 3,5-dinitrobenzyl ester (Aly-DBE), and L-azidonorvaline 3,5-
dinitrobenzyl ester (Anv-DBE) 
Tyr-CME, Asp-DBE, Lys-DBE, Aly-DBE and Anv-DBE were synthesized as 
previously described41,144. 
 
Chemical synthesis of N-(5-FAM)-L-phenylalanine-cyanomethyl ester (Fph-CME) 
 L-phenylalanine-cyanomethyl ester (Phe-CME) was synthesized as previously 
described40. Triethylamine (22 μL, 160 μmol) was added to a mixture of Phe-CME (14.4 
mg, 60 μmol) and 5-carboxyfluorescein succinimidyl ester (Thermo Fisher Scientific Inc., 
19 mg, 40 μmol) in 500 μL of N,N-dimethylformamide and then the mixture was stirred 
at room temperature for 13.5 h. After the reaction, ethyl acetate was added, and the 
solution was treated with 1 M HCl (3 mL × 3) and saturated NaCl (3 mL × 1). The organic 
layer was dried over Na2SO4, and concentrated under reduced pressure. The crude residue 
was dissolved in methanol and injected into a high-pressure liquid chromatography 
(HPLC) system equipped with a Cadenza 5CD-18 reverse-phase chromatography column 
(Code 5CD0Q6). The column was equilibrated with 20% (v/v) acetonitrile in H2O 
containing 0.1% (v/v) TFA, and eluted with a 2.2%/min gradient of 99.9% (v/v) 
acetonitrile in 0.1% (v/v) TFA to 90% (v/v) acetonitrile. The HPLC profile was monitored 
by measuring the absorbance at 494 nm. The fractions of Fph-CME were lyophilized. The 
concentration was determined by absorbance at 494 nm in 500 mM Tris-HCl (pH 8.0). 
Fph-CME: 1H NMR (300 MHz, DMSO-d6, δ): 10.16 (br, 2H), 9.36 (d, J = 7.5 Hz, 
1H), 8.45 (d, J = 0.6 Hz, 1H), 8.19 (dd, J = 8.1, 1.5 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 
7.36–7.20 (m, 5H), 6.68 (d, J = 2.1 Hz, 2H), 6.61–6.52 (m, 4H), 5.05 (s, 1H), 4.87–4.80 
(m, 1H), 3.33–3.14 (m, 2H); 13C NMR (125 MHz, DMSO-d6, δ): 171.0, 168.5, 165.4, 
160.0, 155.6, 152.2, 137.6, 135.4, 135.3, 129.7, 129.5, 128.8, 127.1, 127.0, 124.9, 123.9, 
116.2, 113.1, 109.3, 102.7, 83.8, 54.5, 50.0, 36.2. 
The high-resolution mass spectrum (HRMS) was determined using flow injection 
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(direct electrospray ionization (ESI)-MS) in positive mode (Thermo Exactive). 
Calculated [(M+H)+] m/z for C32H23N2O8
+ = 563.1449, found = 563.1445. 
 
In vitro transcription 
 The tRNAs, eFxs, and dFxs were prepared using run-off in vitro transcription 
with T7 RNA polymerase. DNA templates were modified with 2′-O-methylation at the 
second last nucleotide of the 5′ termini to reduce non-templated nucleotide addition by 
T7 RNA polymerase146. The primers for preparing transcription templates are shown in 
Table 9. All non-methylated primers were purchased from Eurofins Genomics K.K. 
(Japan) and methylated primers were purchased from Gene Design Inc. (Japan). 
 
Expression and purification of maltose binding protein (MBP) -MS2-His6 
The plasmid pMAL-c2g (AmpR) encoding His6-tagged MS2 coat protein (a gift 
from R. Green, Johns Hopkins University) was used to transform E. coli BL21-(DE3) in 
LB medium with 100 μg/mL carbenicillin. A single colony isolated by streaking was used 
to inoculate a 30 mL overnight culture in LB supplemented with 100 μg/mL carbenicillin, 
and 10 mL of this culture was used to inoculate one liter of the same medium. The culture 
was grown to an OD600 of 0.7 at 37°C. The expression of MBP-MS2-His6 was induced 
using 1 mM isopropyl β-D-1-thiogalactopyranoside, and the cells were cultured for 
another 4 h at 37°C. The culture was then centrifuged for 10 min at 4,000× g, the pelleted 
cells were resuspended in 30 mL of lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 
mM imidazole, 6 mM β-mercaptoethanol (β-ME), 1 mM phenylmethanesulfonyl fluoride, 
adjusted to pH 8.0 with NaOH), and were then sonicated. The lysate was clarified twice 
by centrifugation for 20 min at 15,000× g (4°C) and filtered through a Millex-LH 0.45 
μm filter unit (Merck Millipore). MBP-MS2-His6 was purified using a fast protein liquid 
chromatography (FPLC) system (AKTA Avant, GE Healthcare) with a His-Trap HP 
column (GE Healthcare). The column was washed with NiNTA buffer (50 mM NaH2PO4, 
300 mM NaCl, 10mM imidazole, 6 mM β-ME, adjusted to pH 8.0 with NaOH) and the 
protein was eluted with NiNTA buffer containing 250 mM imidazole. Protein-containing 
fractions were pooled and concentrated using a membrane filter (Amicon Ultra15, 3,000 
MWCO, Merck Millipore). The concentrated protein was dialyzed against 20 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 20% glycerol, and 1 mM dithiothreitol (DTT). The protein 
concentration was determined by absorbance at 280 nm, assuming an extinction 
coefficient of 84,800 cm−1 M−1 (calculated on: http://web.expasy.org/protparam/). 
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Expression and purification of tagged ribosomes 
The plasmid pcI857 (KanR) encoding a temperature-sensitive mutant of the lambda 
repressor protein cI (a gift from R. Green, Johns Hopkins University)140 was used to 
transform E. coli DH5α in LB medium containing 50 μg/mL kanamycin. Any 23S rRNA 
mutation of interest was introduced into the plasmid p278 MS2 encoding 23S rRNA 
tagged with the MS2 stem-loop (a gift from R. Green, Johns Hopkins University) by site 
directed mutagenesis using the Quickchange Lightning Site-Directed Mutagenesis kit 
(Agilent Technologies). The primers for mutagenesis are shown in Table 9. The mutations 
were confirmed by sequencing. The mutated plasmid p278 MS2 was used to transform 
DH5α with pcI857 in LB medium containing 100 μg/mL ampicillin and 50 μg/mL 
kanamycin. A colony isolated by streaking was used to inoculate a 50 mL overnight 
culture grown in LB supplemented with 100 μg/mL ampicillin and 50 μg/mL kanamycin 
at 30°C. One liter of this medium was inoculated with 20 mL of an overnight culture and 
grown to an OD600 of 0.7–0.9 at 42°C. The cultures were centrifuged for 10 min at 4,000× 
g and the pelleted cells were resuspended in 5.5 mL ribosome buffer A (20 mM Tris-HCl, 
pH 7.5, 100 mM NH4Cl, 10 mM MgCl2, 0.5 mM EDTA, and 6 mM β-ME). Lysozyme 
(Nacalai Tesque Inc.) was added (final concentration, 0.1 mg/mL) and incubated at 4°C 
for 30 min. This solution was disrupted twice using a cell disruption vessel (Parr 
Instrument Company). The lysate was clarified twice by centrifugation for 15 min at 
15,000× g (4°C), layered onto 10 mL of ribosome buffer D (20 mM Tris-HCl, pH 7.5, 
500 mM NH4Cl, 10 mM MgCl2, 0.5 mM EDTA, 1.1 M sucrose) in a 25PC tube (Hitachi), 
and centrifuged at 104,000× g in an S50A rotor (Hitachi) for 18–20 h at 4°C. Ribosome 
buffer A was used to rinse and then dissolve the pellet, which was then stored at −80°C. 
 Tagged ribosomes were purified using FPLC (AKTA Avant, GE Healthcare). 
First, 2 mg MBP-MS2-His6 was loaded on an MBP Trap HP column (GE Healthcare), 
and the bound protein was washed with ribosome binding buffer (20 mM Tris-HCl, pH 
7.5, 100 mM NH4Cl, and 10 mM MgCl2). Crude ribosomes were loaded onto the column 
and washed with 25 mL of ribosome-binding buffer. Tagged ribosomes bound to MBP-
MS2-His6 were eluted with 20 mL of ribosome-elution buffer (20 mM Tris-HCl, pH 7.5, 
100 mM NH4Cl, 10 mM MgCl2, and 10 mM maltose). Purified tagged ribosomes were 
concentrated to 10–20 μM, and the buffer was exchanged with RE buffer (20 mM 
HEPES-KOH, pH 7.6, 10 mM MgCl2, 50 mM KCl, 1 mM DTT) using membrane 
filtration (Amicon Ultra15, 100,000 MWCO, Merck Millipore). The concentration of 70S 
ribosomes was determined by absorbance at 260 nm using the conversion factor 1 A260 = 
23 pmol. 
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Aminoacylation by flexizymes 
 Aminoacylation reactions of Tyr-CME, Asp-DBE, Lys-DBE, Aly-DBE, and 
Anv-DBE were performed as previously described41. The reaction times were changed to 
30 min (Tyr-CME), 9 hours (Asp-DBE), and 3 hours (Lys-DBE, Aly-DBE and Anv-DBE). 
Aminoacylation of Fph-CME was performed as follows: A mixture of 3 μL of 41.7 μM 
tRNAfMetCAU and 41.7 μM eFx in 83.3 mM HEPES-KOH (pH 7.5) was heated at 95°C 
for 2 min and cooled to room temperature over 5 min. One microliter of 3 M MgCl2 was 
added, and the mixture was transferred to an ice bath, 1 μL of 5 mM Fph-CME was added, 
and the mixture was incubated on ice for 16 h. After the reaction, aminoacyl-tRNA (aa-
tRNA) was precipitated with ethanol as previously described41. 
 
Analysis of acylation 
Ethanol-precipitated aa-tRNA was dissolved in acid-PAGE loading buffer (150 
mM NaOAc, pH 5.2, 10 mM EDTA, and 93% (v/v) formamide) and then loaded on acid-
urea 12% polyacrylamide gels (8 M urea, 50 mM NaOAc, pH 5.2). Electrophoresis was 
performed using 300 V (approximately 10 V cm−1) for 21 h. The gels were stained with 
ethidium bromide and analyzed using an FLA-5100 fluorescent image analyzer (Fujifilm) 
or PharosFX molecular imager (BIO-RAD). Aminoacylation efficiency was calculated 
according to the band intensity of aa-tRNA (A) and free tRNA (T) and is presented as 
(A)/[(A) + (T)]. Because of the fluorescence of Fph-tRNA, the efficiency for Fph-CME 
was calculated using the expression 1−[(Taa+)(Faa−)]/[(Taa−)(Faa+)] according to the band 
intensity of flexizyme in the lane without amino acids (Faa−), flexizyme in the lane with 
amino acids (Faa+), free tRNA in the lane without amino acids (Taa−), and free tRNA in 
the lane with amino acids (Taa+). Values reported are the average of three independent 
reactions, and error bars represent the standard deviation. 
 
DNA templates for translation 
 The DNA templates for translation were prepared using the polymerase chain 
reaction (PCR), and the amplicons were extracted with phenol-chloroform mixture and 
precipitated with ethanol. The DNA templates were purified using 12% native-PAGE, 
and the concentrations were determined by absorbance at 260 nm. The primers for 
preparing DNA templates for translation are shown in Table 9. 
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In vitro translation using the FIT system 
 The FIT system comprised a mixture of all desired components for translation126. 
The tagged-ribosomes and aa-tRNAs were added as necessary in each experiment. The 
composition of the FIT system was as follows: 50 mM HEPES-KOH (pH 7.6), 12 mM 
magnesium acetate, 100 mM potassium acetate, 2 mM spermidine, 20 mM creatine 
phosphate, 2 mM DTT, 2 mM ATP, 2 mM GTP, 1 mM CTP, 1 mM UTP, 0.6 µM MTF, 
2.7 µM IF1, 0.4 µM IF2, 1.5 µM IF3, 0.26 µM EF-G, 10 µM EF-Tu, 10 µM EF-Ts, 0.25 
µM RF1, 0.25 µM RF2, 0.17 µM RF3, 0.5 µM RRF, 0.1 µM T7 RNA polymerase, 4 
µg/mL creatine kinase, 3 µg/mL myokinase, 0.1 µM pyrophosphatase, 0.1 µM nucleotide-
diphosphatase kinase, and 400 nM DNA template. The concentration of EF-Tu and EF-
Ts only in the experiment shown in Figure 35 was increased to 20µM. Translation 
reactions were started by adding aa-tRNAs at 37°C after a 5 min incubation. Translation 
reactions were terminated by adding an equal volume of 2×Tricine-SDS-PAGE loading 
buffer (900 mM Tris-HCl (pH 8.45), 8% (w/v) SDS, 30% (v/v) glycerol). 
In the experiment shown in Figure 29 and 32, the concentration of ribosomes, 
Fph-tRNAfMetCAU, Lys-tRNA
GluE2
CUU, and Tyr-tRNA
GluE2
GUA were 2 μM, 5 μM, 20 μM, 
10 μM, respectively. The sequence of the DNA template was 5′-GGCGT AATAC 
GACTC ACTAT AGGGC TTTAA TAAGG AGAAA AACAT GAAGT ACAAG 
AAGTA CAAGT GAGCT TCG-3′. 
In the experiment shown in Figure 34 and 35, the concentration of the wild-type 
ribosomes, G2251C/G2553C ribosomes, Fph-tRNAfMetCAU-CCA, Fph-tRNA
fMet
CAU-
CGA, Lys-tRNALysCUU-CCA, Lys-tRNA
Lys
CUU-CGA, Asp-tRNA
Asp
GUC-CCA, Aly-
tRNAGluE2GUC-CGA, Tyr-tRNA
Tyr
GUA-CCA, and Anv-tRNA
GluE2
GUA-CGA were 0.1 μM, 
2 μM, 5 μM, 1.5 μM, 10 μM, 3 μM, 10 μM, 3 μM, 10 μM and 3 μM, respectively. The 
sequence of the DNA template was 5′-GGCGT AATAC GACTC ACTAT AGGGC 
TTTAA TAAGG AGAAA AACAT GAAGT ACGAC AAGTA CGACT GAGCT TCG-
3′. 
In the experiment shown in Figure 28, the concentration of wild-type ribosomes, 
Fph-tRNAfMetCAU, Lys-tRNA
AsnE2
CUU, and Tyr-tRNA
AsnE2
GUA were 2 μM, 5 μM, 20 μM, 
10 μM, respectively. The sequence of the DNA template was 5′-GGCGT AATAC 
GACTC ACTAT AGGGC TTTAA TAAGG AGAAA AACAT GAAGT ACAAG 
AAGTA CAAGT GAGCT TCG-3′. 
In the experiment shown in Figure 36, the concentration of the wild-type 
ribosomes, G2251C/G2553C ribosomes, Fph-tRNAfMetCAU-CCA, Fph-tRNA
fMet
CAU-
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CGA, Lys-tRNALysCUU-CCA, Lys-tRNA
Lys
CUU-CGA, Asp-tRNA
Asp
GUC-CCA, and Aly-
tRNAGluE2GUC-CGA were 0.3 μM, 2 μM, 5 μM, 1.5 μM, 20 μM, 6 μM, 10 μM, 3 μM, 
respectively. The sequence of the DNA template was 5′-GGCGT AATAC GACTC 
ACTAT AGGGC TTTAA TAAGG AGAAA AACAT GAAGG ACAAG AAGGA 
CAAGT GAGCT TCG-3′.  
In the experiment shown in Figure 37, the concentration of the wild-type 
ribosomes, G2251C/G2553C ribosomes, Fph-tRNAfMetCAU-CCA, Fph-tRNA
fMet
CAU-
CGA, Lys-tRNALysCUU-CCA, Lys-tRNA
Lys
CUU-CGA, Tyr-tRNA
Tyr
GUA-CCA, and Anv-
tRNAAsnE2GUA-CGA were 0.3 μM, 2 μM, 5 μM, 1.5 μM, 20 μM, 6 μM, 10 μM, 3 μM, 
respectively. The sequence of the DNA template was 5′-GGCGT AATAC GACTC 
ACTAT AGGGC TTTAA TAAGG AGAAA AACAT GAAGT ACAAG AAGTA 
CAAGT GAGCT TCG-3′. 
The aa-tRNAs were prepared by aminoacylation of tRNAs using cognate 
flexizymes. The concentration of aa-tRNA was calculated from acylation efficiency 
shown in Figure 25. 
 
MALDI-TOF analysis 
After incubation, the in vitro translation mixtures were desalted using a C18-tip 
(Nikkyo Technos) and analyzed using MALDI-TOF mass in linear positive modes. All 
MALDI-TOF analysis was performed using an Autoflex II (Bruker Daltonics) or 
ultrafleXtreme (Bruker Daltonics) with external calibration (Peptide Calibration Standard 
II, Bruker Daltonics). 
 
Tricine-SDS-PAGE analysis of translation products 
The quantity of Fph incorporated into peptides was determined using Tricine-
SDS-PAGE as previously described126. The concentration of acrylamide in separation gel 
was 12% for the experiment shown in Figure 28, 29 and 32, 19% for Figure 34 and 20% 
for Figure 36. The fluorescence of the peptides was determined using the FLA-5100 
(Fujifilim) or PharosFX molecular imager (BIO-RAD), and the data were fit to an 
exponential curve using KaleidaGraph (Synergy Software). The amounts of peptides were 
quantified according to that of a fluorescent band generated by a known concentration (0 
μM to 4 μM) of Fph. Values reported are the average of three independent reactions, and 
error bars represent the standard deviation. 
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Quantification of the abundance of tagged ribosome by primer extension 
Primer extension analysis was performed mainly following the previous report140. 
Primer extension using a primer that is complementary to the bases 2254-2273 in 23S 
rRNA produced a dideoxyguanosine stop at +2 for tagged G2252C , +3 for tagged 
G2251C, or +6 for untagged wild-type ribosomes, or a dideoxythymidine stop at +3 for 
tagged G2251A or +7 for untagged wild-type ribosomes. Primer extension using a primer 
that is complementary to the bases 2556-2575 in 23S rRNA produced a dideoxyguanosine 
stop at +3 for tagged G2553C or +5 for untagged wild-type ribosomes, or a 
dideoxythymidine stop at +3 for tagged G2553A or +9 for untagged wild-type ribosomes. 
Ribosomal RNAs were extracted from purified ribosomes by phenol-chloroform 
extraction and ethanol precipitation. Primer extension was carried out as follows: A 
mixture of 7 μL of 57.1 nM rRNA, 171.4 nM [32P] 5′-end labeled primer, 7.14 mM each 
dATP/dCTP/dTTP/ddGTP or dATP/dGTP/dCTP/ddTTP was heated at 65°C for 5 min 
and cooled on ice 1 min. Two microliter of 5× FS buffer (Thermo Fisher Scientific Inc.), 
0.5 μL of 0.1 M DTT and 0.5 μL of SuperScriptTM III (Thermo Fisher Scientific Inc.) 
were added, and the mixture were incubated at 55°C for 1 hour. Primer extension products 
were resolved on a 15% denaturing polyacrylamide gel (8M urea, 1×TBE) and the 
intensities of the bands were quantified using FLA-5100 (Fujifilim). 
 
Gel-shift analysis of ternary complex of EF-Tu, GTP and aa-tRNA 
Binding of EF-Tu to aa-tRNAs was investigated by following previous report147. 
First, 10 µM EF-Tu was preincubated with 1 mM GTP at 37°C for 15 min in 5 µL total 
volume containing 70 mM HEPES-KOH (pH 7.6), 52 mM NH4OAc, 8 mM Mg(OAc)2, 
30 mM KCl, 0.8 mM DTT, 1.6 µM GDP, 6% glycerol, 10 mM phosphoenolpyruvate, and 
0.08 U/µL pyruvate kinase. After aminoacylation reaction by flexizyme, the ethanol 
precipitated mixtures which contain flexizymes, aa-tRNAs and tRNAs were resuspended 
in 6 mM KOAc at 8.3 µM final concentration of aa-tRNA. The concentrations of aa-
tRNAs were calculated from acylaton efficiency shown in Figure 25. This 3 µL aa-tRNA 
solution and 2 µL of ternary complex buffer, containing 150 mM HEPES-KOH (pH 7.6), 
195 mM NH4OAc, and 30 mM Mg(OAc)2 were added to the preincubated EF-Tu solution. 
The mixture was incubated at 37°C for 10 min. Native-PAGE was performed using 8% 
polyacrylamide gels at 4°C in a running buffer containing 50 mM Tris-HCl (pH 6.8), 65 
mM NH4OAc, and 10 mM Mg(OAc)2. Gels were stained by SimplyBlue
TM SafeStain 
(Thermo Fisher Scientific Inc.). Intensities of bands were analyzed by Multi Gauge 
(Fujifilim). 
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Table 9 | Primers used in the chapter 3. 
Sequence (5′ to 3′) used for 
GGCGTAATACGACTCACTATAG dFx, eFx, tRNA, DNA template 
GTAATACGACTCACTATAGGATCGAAAGATTTCCGC dFx-NNU and eFx-NNU 
AACGCCATGTACCCTTTCGGGGATGCGGAAATCTTTCGATCC dFx-NNU 
AACGCTAATCCCCTTTCGGGGCCGCGGAAATCTTTCGATCC eFx-NNU 
AC(M)CTAACGCCATGTACCCTTTCGGG dFx-GGU 
AC(M)CTAACGCTAATCCCCTTTCGGG eFx-GGU 
AG(M)CTAACGCCATGTACCCTTTCGGG dFx-GCU 
AG(M)CTAACGCTAATCCCCTTTCGGG eFx-GCU 
AC(M)GTAACGCCATGTACCCTTTCGGG dFx-CGU 
AC(M)GTAACGCTAATCCCCTTTCGGG eFx-CGU 
AG(M)GTAACGCCATGTACCCTTTCGGG dFx-GGU 
AG(M)GTAACGCTAATCCCCTTTCGGG eFx-GGU 
AC(M)TTAACGCCATGTACCCTTTCGGG dFx-AGU 
AC(M)TTAACGCTAATCCCCTTTCGGG eFx-AGU 
GTAATACGACTCACTATACGCGGGGTGGAGCAGCCTGGTAGCTCGTCGG tRNAfMetCAU-NNA 
GAACCGACGATCTTCGGGTTATGAGCCCGACGAGCTACCAGGCT tRNAfMetCAU-NNA 
TTGCGGGGGCCGGATTTGAACCGACGATCTTCGGG tRNAfMetCAU-NNA 
GGCGTAATACGACTCACTATAC tRNAfMetCAU-NNA 
TG(M)GTTGCGGGGGCCGGATTTG tRNAfMetCAU-CCA 
TG(M)CTTGCGGGGGCCGGATTTG tRNAfMetCAU -GCA 
TC(M)GTTGCGGGGGCCGGATTTG tRNAfMetCAU -CGA 
TC(M)CTTGCGGGGGCCGGATTTG tRNAfMetCAU -GGA 
TA(M)GTTGCGGGGGCCGGATTTG tRNAfMetCAU -CUA 
GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGA tRNAGluE2NNN-NNA 
CGTCCCCTAGGGGATTCGAACCCCTGTTACCGCC tRNAGluE2NNN-NNA 
TATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTCT tRNAGluE2CUU-NNA 
GAACCCCTGTTACCGCCTTAAGAGGGCGGTGTCCTGG tRNAGluE2CUU-NNA 
TATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCCTGT tRNAGluE2GUA-NNA 
GAACCCCTGTTACCGCCTTTACAGGGCGGTGTCCTGG tRNAGluE2GUA-NNA 
TATAGTCCCCTTCGTCTAGAGGCCCAGGACACCGCCTTGT tRNAGluE2GUC-NNA 
GAACCCCTGTTACCGCCTTGACAAGGCGGTGTCCTGG tRNAGluE2GUC-NNA 
TG(M)GCGTCCCCTAGGGGATTC tRNAGluE2NNN-CCA 
TG(M)CCGTCCCCTAGGGGATTC tRNAGluE2NNN-GCA 
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Sequence (5′ to 3′) used for 
TC(M)GCGTCCCCTAGGGGATTC tRNAGluE2NNN-CGA 
TC(M)CCGTCCCCTAGGGGATTC tRNAGluE2NNN-GGA 
TA(M)GCGTCCCCTAGGGGATTC tRNAGluE2NNN-CUA 
TATAGGGTCGTTAGCTCAGTTGGTAGAGCAGTTGACTCTTAATC tRNALysCUU-NNA 
GGCGTAATACGACTCACTATAGGGTCGTTAGCTCAGTTG tRNALysCUU-NNA 
TTCGAACCTGCGACCAATTGATTAAGAGTCAACTGCTCTACC tRNALysCUU-NNA 
TGGGTCGTGCAGGATTCGAACCTGCGACCAATTGATT tRNALysCUU-NNA 
TG(M)GTGGGTCGTGCAGGATTCG tRNALysCUU-CCA 
TC(M)GTGGGTCGTGCAGGATTCG tRNALysCUU-CGA 
TATAGGAGCGGTAGTTCAGTCGGTTAGAATACCTGCCTGT tRNAAspGUC-NNA 
GGCGTAATACGACTCACTATAGGAGCGGTAGTTCAGTC tRNAAspGUC-NNA 
GAACCCGCGACCCCCTGCGTGACAGGCAGGTATTCTAACCG tRNAAspGUC-NNA 
CGGAACGGACGGGACTCGAACCCGCGACCCCC tRNAAspGUC-NNA 
TG(M)GCGGAACGGACGGGACT tRNAAspGUC-CCA 
AGGTGGGGTTCCCGAGCGGCCAAAGGGAGCAGACTGTAAATCT tRNATyrGUA-NNA 
GGCGTAATACGACTCACTATAGGTGGGGTTCCCGAG tRNATyrGUA-NNA 
GAACCTTCGAAGTCTGTGACGGCAGATTTACAGTCTGCTCCCT tRNATyrGUA-NNA 
TGGTGGGGGAAGGATTCGAACCTTCGAAGTCTGTGA tRNATyrGUA-NNA 
TG(M)GTGGTGGGGGAAGGATTCG tRNATyrGUA-CCA 
GTAATACGACTCACTATAGGCTCTGTAGTTCAGTCGGTAGAACGGCGGA tRNAAsnE2NNN-NNA 
CGGCTCTGACTGGACTCGAACCAGTGACATACGGA tRNAAsnE2NNN-NNA 
GAACCAGTGACATACGGATTAAGAGTCCGCCGTTCTACCGACT tRNAAsnE2CUU-NNA 
GAACCAGTGACATACGGATTTACAGTCCGCCGTTCTACCGACT tRNAAsnE2GUA-NNA 
GAACCAGTGACATACGGATTGACAGTCCGCCGTTCTACCGACT tRNAAsnE2GUC-NNA 
TG(M)GCGGCTCTGACTGGACTC tRNAAsnE2NNN-CCA 
TG(M)CCGGCTCTGACTGGACTC tRNAAsnE2NNN-GCA 
TC(M)GCGGCTCTGACTGGACTC tRNAAsnE2NNN-CGA 
TC(M)CCGGCTCTGACTGGACTC tRNAAsnE2NNN-GGA 
TA(M)GCGGCTCTGACTGGACTC tRNAAsnE2NNN-CUA 
ATACGACTCACTATAGGGCTTTAATAAGGAGAAAAACATG DNA template 
GGCGTAATACGACTCACTATAGGGCTTT DNA template 
GTACTTCTTGTACTTCATGTTTTTCTCCTTATTAAAGCC DNA template (Heptapeptide-1) 
GTACTTGTCGTACTTCATGTTTTTCTCCTTATTAAAGCC DNA template (Heptapeptide-2, 3) 
GTCCTTCTTGTCCTTCATGTTTTTCTCCTTATTAAAGCC DNA template (Heptapeptide-4, 5) 
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Sequence (5′ to 3′) used for 
CGAAGCTCACTTGTACTTCTTGTACTTCATGTTTTTC DNA template (Heptapeptide-1) 
CGAAGCTCAGTCGTACTTGTCGTACTTCATGTTTTTC DNA template (Heptapeptide-2, 3) 
CGAAGCTCACTTGTCCTTCTTGTCCTTCATGTTTTTC DNA template (Heptapeptide-4, 5) 
GGTGGGTAGTTTGACTGCGGCGGTCTCCTCCTAAAGAG Quick Change (G2251C) 
CTCTTTAGGAGGAGACCGCCGCAGTCAAACTACCCACC Quick Change (G2251C) 
GGTGGGTAGTTTGACTGGCGCGGTCTCCTCCTAAAGAG Quick Change (G2252C) 
CTCTTTAGGAGGAGACCGCGCCAGTCAAACTACCCACC Quick Change (G2252C) 
GGTGGGTAGTTTGACTGCCGCGGTCTCCTCCTAAAGAG Quick Change (G2251C/G2252C) 
CTCTTTAGGAGGAGACCGCGGCAGTCAAACTACCCACC Quick Change (G2251C/G2252C) 
GGTGGGTAGTTTGACTGAGGCGGTCTCCTCCTAAAGAG Quick Change (G2251A) 
CTCTTTAGGAGGAGACCGCCTCAGTCAAACTACCCACC Quick Change (G2251A) 
GTCCCAAGGGTATGGCTCTTCGCCATTTAAAGTGGTAC Quick Change (G2553C) 
GTACCACTTTAAATGGCGAAGAGCCATACCCTTGGGAC Quick Change (G2553C) 
GTCCCAAGGGTATGGCTATTCGCCATTTAAAGTGGTAC Quick Change (G2553A) 
GTACCACTTTAAATGGCGAATAGCCATACCCTTGGGAC Quick Change (G2553A) 
TACTCTTTAGGAGGAGACCG Primer extension (2251, 2252) 
GCGTACCACTTTAAATGGCG Primer extension (2553) 
CCACCCTTTAATGTTTGATGTTC Sequencing (2251, 2252) 
CAGTCAAGCTGGCTTATGC Sequencing (2251, 2252) 
CATATCGACGGCGGTGTTTG Sequencing (2553) 
GGCAGATAGGGACCGAAC Sequencing (2553) 
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Table 10 | RNAs prepared in the chapter 3. N means A/U/G/C, italic types indicate 
ribonucleotides. 
 
Name Sequence (5′ to 3′) 
eFx-NNU GGAUCGAAAGAUUUCCGCGGCCCCGAAAGGGGAUUAGCGUUANNU 
dFx-NNU GGAUCGAAAGAUUUCCGCAUCCCCGAAAGGGUACAUGGCGUUANNU 
tRNAfMetCAU-NNA 
CGCGGGGUGGAGCAGCCUGGUAGCUCGUCGGGCUCAUAACCCGAAGAUCGUCGGUUCAAAU
CCGGCCCCCGCAANNA 
tRNAEnAsnCUU-NNA 
GGCUCUGUAGUUCAGUCGGUAGAACGGCGGACUCUUAAUCCGUAUGUCACUGGUUCGAGU
CCAGUCAGAGCCGNNA 
tRNAEnAsnGUA-NNA 
GGCUCUGUAGUUCAGUCGGUAGAACGGCGGACUGUAAAUCCGUAUGUCACUGGUUCGAGU
CCAGUCAGAGCCGNNA 
tRNAEnAsnGUC-NNA 
GGCUCUGUAGUUCAGUCGGUAGAACGGCGGAUUGUCAAUCCGUAUGUCACUGGUUCGAGU
CCAGUCAGAGCCGNNA 
tRNAEnGluCUU-NNA 
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUCUUAAGGCGGUAACAGGGGUUCGAAUC
CCCUAGGGGACGNNA 
tRNAEnGluGUA-NNA 
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCUGUAAAGGCGGUAACAGGGGUUCGAAUC
CCCUAGGGGACGNNA 
tRNAEnGluGUC-NNA 
GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCUUGACAAGGCGGUAACAGGGGUUCGAAUC
CCCUAGGGGACGNNA 
tRNALysCUU-NNA 
GGGUCGUUAGCUCAGUUGGUAGAGCAGUUGACUCUUAAUCAAUUGGUCGCAGGUUCGAAU
CCUGCACGACCCANNA 
tRNATyrGUA-NNA 
GGUGGGGUUCCCGAGCGGCCAAAGGGAGCAGACUGUAAAUCUGCCGUCACAGACUUCGAAG
GUUCGAAUCCUUCCCCCACCANNA 
tRNAAspGUC-NNA 
GGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCCUGUCACGCAGGGGGUCGCGGGUUCGAG
UCCCGUCCGUUCCGNNA 
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Chapter 4 
General conclusion (abridged) 
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 In natural, each ARS specifically recognizes each tRNA and amino acid, and 
tRNAs are specifically aminoacylated with cognate amino acids by cognate ARSs. This 
rigorously-defined correspondence of tRNAs to amino acids defines genetic code, which 
is essential for accurate translation of mRNAs to proteins in living organism. However, 
this specific aminoacylation reaction is not favored in the case of application of 
aminoacylation to other studies or engineering of translation machinery, because it is 
difficult to arbitrarily aminoacylate RNAs with various amino acids. Flexizymes are in 
vitro selected aminoacylation ribozymes which have two unique characteristics; (i) using 
various substrates including both natural amino acids and ncAAs. (ii) recognizing 
substrate RNA via two consecutive base pairs, which can be substituted with other base 
pairs65. These characteristics enable to flexibly aminoacylate RNAs bearing various 3′ 
ends with various amino acids including both canonical and noncanonical amino acids.  
In the study described in chapter 3, compensatory mutated flexizymes 
aminoacylated tRNAs bearing mutation at the 3′ end. In addition to C74N/C75N mutants, 
A76N mutant tRNA also can be aminoacylated by prototype of flexizymes “pre-24”40,58, 
which suggests that also compensatory mutated flexizymes (eFx, dFx and aFx) can 
aminoacylate A76N mutant tRNAs. These results indicate that wild-type and 
compensatory mutated flexizymes have great potential to charge various amino acids onto 
any tRNAs bearing NNN-3′ end. Therefore A76 of tRNA is also candidate to be mutated 
for engineering of peptidyl transferase center to develop more active orthogonal 
translation machinery. However, further engineering of ribosome and translation factors 
will be necessary because A76 residue is important for formation of aa-tRNA•EF-
Tu•GTP ternary complex141 and translocation of peptidyl-tRNA from A-site to P-site155.  
In the study in chapter 3, only in vitro translation activity and orthogonality was 
demonstrated. If this orthogonal translation machinery will work in vivo, it will be 
possible that engineered proteins containing ncAAs are expressed without affecting the 
endogenous translation machinery. In order to achieve this, there are problems to be 
solved. First is the low efficiency of translation by orthogonal ribosome and tRNA pair. 
In this study short seven polypeptide was expressed but it is necessary to increase 
translation efficiency in order to produce full-length protein. Second is the 
misincorporation of aa-tRNAs into non-cognate ribosomes. In the case of FIT system, the 
amount of translation components including ARS, factors, amino acids, tRNAs and 
ribosomes can be changed. However, it is very difficult to express the appropriate amount 
of translation components in vivo to avoid the misincorporation. Further engineering of 
translation components as described above will be necessary to solve these problems. 
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Finally, it is necessary that orthogonal ribosome-tRNA pair translates the specific mRNA 
encoding target protein in order not to affect the endogenous translation of other proteins. 
To achieve this, we need to construct orthogonal ribosome-tRNA-mRNA. Orthogonal 
ribosome-mRNA pair was already reported, but 16S rRNA was engineered in the study121-
123. Therefore, orthogonal 50S subunit -30S subunit pair will be needed to construct 
orthogonal ribosome-tRNA-mRNA. As described above, there are many problems to 
express the orthogonal translation machinery in vivo, but these will be solved in future. 
 Until now, flexizymes has been mainly applied for preparing aa-tRNA bearing 
ncAAs used for genetic code reprogramming to produce non-standard peptides25. 
However, as discussed above, aminoacylation at 3′ end of RNA with various amino acids 
by flexizymes has a great potential to be applied for various RNA studies. The 
development of orthogonal translation system opens an entrance to a new opportunity of 
in vitro synthetic biology.  
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